Abstract
Lung cancer is the leading cause of cancer-related death in both men and women. Several types of nanocarriers have succeeded in delivering both chemotherapeutic agents and genes to lung tumor sites. Among them, solid lipid nanoparticles (SLNs) are newly emerging surrogates to traditional colloidal delivery systems which hold great promise in achieving drug localization at the site of action via both passive and active targeting based on their unique features to incorporate hydrophilic or hydrophobic payloads in addition to proteins and nucleic acids. SLNs open novel frontiers for prolonged and site-specific drug and gene delivery. This chapter emphasizes the role of SLNs in drug and gene delivery via different routes of administration (intravenous, oral, or inhalation). In addition, it highlights the safety profile of biocompatible SLNs that are highly tolerable by the lungs for lung cancer management.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
